Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Joseph D TrimarcoDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA.ORCID 0000-0001-5463-7144
M Ariel SpurrierDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA.ORCID 0000-0002-3314-9683
Samantha SkavicusDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA.ORCID 0009-0003-1380-8551
Zhaochen LuoDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA.
Moumita DuttaDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Katarzyna JanowskaDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Priyamvada AcharyaDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Brook E HeatonDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA.ORCID 0000-0003-2839-3806
Nicholas S HeatonDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA.ORCID 0000-0002-5307-3428
Funding
Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component A: Vaccine Center75N93019C00050 · NIAID · DUKE UNIVERSITY · PI MOODY, TONY · 2019 to 2025
$69.1M
Regional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3M
Resources and Workforce Development for the Regional Biocontainment LaboratoriesUC7AI180254 · NIAID · DUKE UNIVERSITY · PI Herman F Staats · 2023 to 2026
$14.0M
Viral Oncology Training GrantT32CA009111 · NCI · DUKE UNIVERSITY · PI LUFTIG, MICAH A. · 1985 to 2023
$8.9M
Regional Biocontainment Laboratories Facility and Building System Upgrades SupportG20AI167200 · NIAID · DUKE UNIVERSITY · PI STAATS, HERMAN F · 2021 to 2022
$6.6M
The pathogenic effects of epithelial cells surviving direct influenza virus infectionR01AI137031 · NIAID · DUKE UNIVERSITY · PI Nicholas S Heaton · 2019 to 2026
$4.5M
Control of influenza virus induced type I interferon signaling during pregnancyR01AI168107 · NIAID · DUKE UNIVERSITY · PI Nicholas S Heaton · 2023 to 2026
In early 2024, a clade 2.3.4.4b high pathogenic H5N1 avian influenza virus was detected in dairy cows and humans in the United States. Since then, it has spread to herds in at least 13 states and caused symptomatic disease in at least fifteen people. To facilitate rapid testing of existing and novel countermeasures, here, we report the development of an H5N1 viral reverse genetic system, its use to produce fluorescent and bioluminescent variant strains, and their utility in high-throughput evaluation of antiviral interventions.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Fluorescent and bioluminescent bovine H5N1 influenza viruses for evaluation of antiviral interventions. · full record | OpenQuestion